Actavis launches Donepezil in eight EU markets
Following patent expiry in the UK and Sweden
Icelandic generics group Actavis has launched Donepezil, a generic version of Eisai and Pfizer’s drug Aricept, in some of Europe’s biggest markets, following patent expiry in the UK and Sweden.
The conventional tablets were launched in Germany, France, Italy, Spain, the UK, Denmark, Sweden and Austria this week.
The generic donepezil tablets were developed by Actavis R&D and are manufactured by Actavis in Malta.
Actavis is also bringing Donepezil oro-dispersible tablets to market following patent expiry in the UK and Sweden. The firm has already launched Donepezil in a number of patent-free markets.
The drug is indicated for the treatment of mild to moderately severe Alzheimer’s disease.
The brand product had sales in the EU of around €475.6m for the 12 months ending September 2011, according to IMS Health figures.
